AI-generated analysis. Always verify with the original filing.
Unicycive Therapeutics announced its full year 2025 financial results, reporting a reduced net loss of $26.6 million and providing a business update on its lead drug candidate OLC, which has a PDUFA target action date of June 29, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende
. Financial Statements and Exhibits** (d) Exhibits. | 99.1 | | Press Release of Unicycive Therapeutics, Inc. dated March 30, 2026. | |---|---|---| | 104 | | Cov
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $9.10 | |
| General and Administrative Expenses | $20.40 | |
| Other Income | $3.00 | |
| Net Loss Attributable to Common Stockholders | $26.60 | |
| Net Loss Per Share Attributable to Common Stockholders | $1.67 |